EP2709646A4 - Dry powder vancomycin compositions and associated methods - Google Patents

Dry powder vancomycin compositions and associated methods

Info

Publication number
EP2709646A4
EP2709646A4 EP12785744.9A EP12785744A EP2709646A4 EP 2709646 A4 EP2709646 A4 EP 2709646A4 EP 12785744 A EP12785744 A EP 12785744A EP 2709646 A4 EP2709646 A4 EP 2709646A4
Authority
EP
European Patent Office
Prior art keywords
dry powder
associated methods
vancomycin compositions
powder vancomycin
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP12785744.9A
Other languages
German (de)
French (fr)
Other versions
EP2709646A1 (en
Inventor
John Lord
Jaakko Taneli Jouhikainen
Herman E Snyder
Pravin Soni
Mei-Chang Kuo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Savara Inc
Original Assignee
Savara Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Savara Inc filed Critical Savara Inc
Publication of EP2709646A1 publication Critical patent/EP2709646A1/en
Publication of EP2709646A4 publication Critical patent/EP2709646A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
EP12785744.9A 2011-05-19 2012-05-21 Dry powder vancomycin compositions and associated methods Withdrawn EP2709646A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161487971P 2011-05-19 2011-05-19
PCT/US2012/038775 WO2012159103A1 (en) 2011-05-19 2012-05-21 Dry powder vancomycin compositions and associated methods

Publications (2)

Publication Number Publication Date
EP2709646A1 EP2709646A1 (en) 2014-03-26
EP2709646A4 true EP2709646A4 (en) 2015-05-13

Family

ID=47177374

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12785744.9A Withdrawn EP2709646A4 (en) 2011-05-19 2012-05-21 Dry powder vancomycin compositions and associated methods

Country Status (11)

Country Link
EP (1) EP2709646A4 (en)
JP (1) JP6012716B2 (en)
KR (1) KR101763195B1 (en)
CN (1) CN103717231B (en)
AU (1) AU2012254999B2 (en)
BR (1) BR112013029803B1 (en)
CA (2) CA2836643C (en)
IL (1) IL229506B (en)
MX (1) MX346244B (en)
SG (1) SG195038A1 (en)
WO (1) WO2012159103A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006322076C1 (en) 2005-12-08 2013-11-14 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
MX2015006681A (en) 2012-11-29 2016-04-06 Insmed Inc Stabilized vancomycin formulations.
CA2897651C (en) 2013-01-10 2021-09-21 Pulmokine, Inc. Non-selective kinase inhibitors
CN104043104B (en) * 2013-03-15 2018-07-10 浙江创新生物有限公司 The spray dried powder and its industrialized process for preparing of hydrochloric vancomycin
CA2926793C (en) 2013-10-11 2022-11-22 Lawrence S. ZISMAN Spray-dry formulations for treating pulmonary arterial hypertension
WO2015128495A1 (en) * 2014-02-28 2015-09-03 Algipharma As Use of alginate oligomers in the treatment of cystic fibrosis and other conditions associated with defective cftr ion channel function
ES2903419T3 (en) 2014-03-14 2022-04-01 Azurity Pharmaceuticals Inc Composition and method for vancomycin oral liquid
ES2981634T3 (en) 2014-05-15 2024-10-09 Insmed Incorporated Methods for treating nontuberculous pulmonary mycobacterial infections
RS59851B1 (en) * 2014-11-06 2020-02-28 Xellia Pharmaceuticals Aps Glycopeptide compositions
WO2016127087A1 (en) 2015-02-06 2016-08-11 Latitude Pharmaceuticals, Inc. Aqueous solution formulations of vancomycin
GB201609940D0 (en) * 2016-06-07 2016-07-20 Novabiotics Ltd Microparticles
CA3041679A1 (en) 2016-10-27 2018-05-03 Lawrence S. ZISMAN Combination therapy for treating pulmonary hypertension
CN106963939A (en) * 2017-03-22 2017-07-21 永信药品工业（昆山）股份有限公司 Vancomycin hydrochloride pharmaceutical composition and preparation method thereof
CA3062570A1 (en) * 2017-05-22 2018-11-29 Insmed Incorporated Lipo-glycopeptide cleavable derivatives and uses thereof
EP3773505A4 (en) 2018-03-30 2021-12-22 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
WO2020081599A1 (en) * 2018-10-15 2020-04-23 Savara Inc. Separation of vancomycin and its degradation products

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997041833A1 (en) * 1996-05-08 1997-11-13 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
WO2001013893A2 (en) * 1999-08-25 2001-03-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles
WO2001032144A1 (en) * 1999-10-29 2001-05-10 Inhale Therapeutic Systems, Inc. Dry powder compositions having improved dispersivity
WO2003037303A1 (en) * 2001-11-01 2003-05-08 Nektar Therapeutics Spray drying methods and compositions thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
NO160330C (en) 1982-10-08 1989-04-12 Glaxo Group Ltd DEVICE FOR AA ADMINISTRATING MEDICINES TO PATIENTS AND MEDICINAL PACKAGING FOR THE DEVICE.
NO166268C (en) 1985-07-30 1991-07-03 Glaxo Group Ltd DEVICE FOR ADMINISTRATING PATIENTS TO PATIENTS.
JPH03193735A (en) * 1989-12-22 1991-08-23 Shionogi & Co Ltd Stabilized composition of glycopeptide-based antibiotic
JPH05963A (en) 1990-04-13 1993-01-08 Toray Ind Inc Polypeptide composition
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
JP4142149B2 (en) * 1997-07-10 2008-08-27 明治製菓株式会社 Vancomycin lyophilized formulation
DE10358387A1 (en) * 2003-12-13 2005-07-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powder containing low molecular weight dextran and process for their preparation
FR2872044B1 (en) * 2004-06-28 2007-06-29 Flamel Technologies Sa PHARMACEUTICAL FORMULATION BASED ON ANTIBIOTICS IN THE MICROCAPSULAR FORM
EP2050437A1 (en) * 2007-10-15 2009-04-22 Laboratoires SMB Improved pharmaceutical dry powder compositions for inhalation.
JP2012505223A (en) * 2008-10-07 2012-03-01 エムペックス・ファーマシューティカルズ・インコーポレーテッド Aerosol fluoroquinolone formulation for improved pharmacokinetics
EP2410981B2 (en) * 2009-03-26 2020-02-26 Pulmatrix Operating Company, Inc. Dry powder formulations and methods for treating pulmonary diseases
WO2010111641A2 (en) * 2009-03-26 2010-09-30 Pulmatrix, Inc. Methods for treating and preventing pneumonia and ventilator-associated tracheobronchitis

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997041833A1 (en) * 1996-05-08 1997-11-13 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
WO2001013893A2 (en) * 1999-08-25 2001-03-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles
WO2001032144A1 (en) * 1999-10-29 2001-05-10 Inhale Therapeutic Systems, Inc. Dry powder compositions having improved dispersivity
WO2003037303A1 (en) * 2001-11-01 2003-05-08 Nektar Therapeutics Spray drying methods and compositions thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Handbook of Pharmaceutical Excipients. Fifth Edition", 2006, PHARMACEUTICAL PRESS, article "Leucine", pages: 412, XP002729817 *
M. J. DE JESUS VALLE ET AL: "Pulmonary versus Systemic Delivery of Antibiotics: Comparison of Vancomycin Dispositions in the Isolated Rat Lung", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 51, no. 10, 6 August 2007 (2007-08-06), pages 3771 - 3774, XP055140353, ISSN: 0066-4804, DOI: 10.1128/AAC.00099-07 *
PRAJAKTA S. GADGILP: "A comparative study between high potency dry powder inhalation and nebulized solution of vancomycin hydrochloride for lung delivery", 11 August 2011 (2011-08-11), pages FP - 109, XP055140679, Retrieved from the Internet <URL:http://search.proquest.com/pqdtscieng/docview/889930798as02134> [retrieved on 20141111] *
REINHARD VEHRING: "Pharmaceutical Particle Engineering via Spray Drying", PHARMACEUTICAL RESEARCH, vol. 25, no. 5, 28 November 2007 (2007-11-28), KLUWER ACADEMIC PUBLISHERS-PLENUM PUBLISHERS, NL, pages 999 - 1022, XP019613056, ISSN: 1573-904X *
See also references of WO2012159103A1 *

Also Published As

Publication number Publication date
CA2836643C (en) 2017-11-14
WO2012159103A1 (en) 2012-11-22
EP2709646A1 (en) 2014-03-26
CN103717231A (en) 2014-04-09
KR20140032450A (en) 2014-03-14
KR101763195B1 (en) 2017-07-31
CA2836643A1 (en) 2012-11-22
MX2013013503A (en) 2014-05-12
SG195038A1 (en) 2013-12-30
CN103717231B (en) 2016-08-17
BR112013029803B1 (en) 2021-07-13
JP2014515356A (en) 2014-06-30
CA2981038C (en) 2018-09-25
JP6012716B2 (en) 2016-10-25
IL229506B (en) 2019-07-31
MX346244B (en) 2017-03-13
NZ704819A (en) 2016-05-27
NZ618002A (en) 2015-03-27
CA2981038A1 (en) 2012-11-22
IL229506A0 (en) 2014-01-30
BR112013029803A2 (en) 2017-01-17
AU2012254999B2 (en) 2016-02-11

Similar Documents

Publication Publication Date Title
IL229506B (en) Dry powder vancomycin compositions and associated methods
HK1199694A1 (en) Probiotic compositions and methods
ZA201408594B (en) Xylitol-based anti-mucosal compositions and related methods and compositions
EP2591359A4 (en) Methods and compositions for quantifying exosomes
PL2624702T3 (en) Anti-biofilm compositions and methods for using
ZA201306316B (en) Methods and compositions for preparing noribogaine from voacangine
EP2691397A4 (en) Methods and compositions for preparing noribogaine from voacangine
EP2629742A4 (en) Hair-mending compositions and associated methods
GB201102237D0 (en) Particle formulation
ZA201304201B (en) Composition comprising insecticide-wax particles
EP2854530A4 (en) Compositions and methods for -glucan immunotherapy
EP2785176A4 (en) Anti-microbial compositions and related methods
EP2555788A4 (en) Methods and compositions for cardioprotection and cardioregeneration
IL250307A0 (en) Fumigant compositions and methods
GB201315350D0 (en) Methods and compositions
ZA201304122B (en) Methods and compositions for drying coal
EP2762129A4 (en) Cosmetic composition and cosmetic
ZA201308892B (en) Compositions and methods
GB201315347D0 (en) Methods and compositions
HK1201451A1 (en) Compositions and methods
EP2575869A4 (en) Peptide particle formulation
EP2668044A4 (en) Compositions and their use
GB201018650D0 (en) Methods and compositions
GB201106357D0 (en) Composition and uses thereof
EP2766357A4 (en) Meso-biliverdin compositions and methods

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20131209

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1194310

Country of ref document: HK

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/14 20060101AFI20141114BHEP

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/14 20060101AFI20141121BHEP

RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20150415

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/14 20060101AFI20150409BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20161118

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20220628

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1194310

Country of ref document: HK